COLO B Coloplast A/S Class B

Coloplast A/S - Transactions in connection with share buy-back programme, week 12

Coloplast A/S - Transactions in connection with share buy-back programme, week 12

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 16 – 20 March 2020:

DateNumber of sharesAverage purchase price, DKKTransaction value, DKK
16 March 2020810834.97676,326
17 March 20201,000867.70867,000
18 March 2020500917.66458,830
19 March 2020174892.77155,342
20 March 20205,000949.494,747,450
Accumulated until now under the programme161,685898.88145,334,700

Henceforth, Coloplast owns 3,257,317 treasury B shares of DKK 1 equal to 1.51% of the company’s total share capital.

An overview showing the transaction data for the period 16 – 20 March 2020 is enclosed.



Kind regards,

Investor Relations

Coloplast A/S

Tel.

 

For further information, please contact

  

Investors and analysts

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. /

Email:

                                                                                       

Press and the media

Lina Danstrup

Sr. Media Relations Manager

Tel. 4911 2607

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Danmark

CVR NR. 69749917

Website

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-03.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments

EN
23/03/2020

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Buy, TP: DKK1050.00) - Next up: ‘Meet the Management’

Q2 organic growth of 7.5% YOY was in line with our forecast and consensus, but the EBIT margin (b.s.i.) of 27.2% missed. Coloplast revised its 2023/24 reported revenue growth guidance to 10–11% (previously c11%) on FX, but kept its c8% organic growth and 27–28% EBIT margin (b.s.i.) guidance. At the upcoming ‘Meet the Management’ event, we expect an update on its clinical performance programme and a deep-dive into Kerecis. We reiterate our BUY and DKK1,050 target price.

COLO B COLOPLAST A/S CLASS B
5h 5h 1 EN
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
13h / 41m 13h / 41m 1 EN
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
V1S ARKEMA
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
14h / 11m 14h / 11m 1 FR
Oliver Metzger
  • Oliver Metzger
COLO B Coloplast A/S C...

Coloplast : Q2 review – Top and bottom line a slight miss, focus on LC...

>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...

COLO B COLOPLAST A/S CLASS B
15h / 29m 15h / 29m 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
16h / 35m 16h / 35m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch